Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
10.80
+0.74 (7.36%)
At close: Nov 22, 2024, 4:00 PM
10.93
+0.13 (1.20%)
After-hours: Nov 22, 2024, 7:31 PM EST
Kura Oncology Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
142
Market Cap
839.85M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Healthcare Services Group | 1.70B |
Pacira BioSciences | 694.96M |
Avanos Medical | 681.50M |
Castle Biosciences | 311.88M |
Paragon 28 | 245.00M |
Cytek Biosciences | 201.21M |
AbCellera Biologics | 32.96M |
Capricor Therapeutics | 23.23M |
KURA News
- 2 days ago - Kura Oncology to partner with Kyowa Kirin for blood cancer therapy - Reuters
- 2 days ago - Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias - GlobeNewsWire
- 13 days ago - Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - GlobeNewsWire
- 22 days ago - Kura Oncology to Report Third Quarter 2024 Financial Results - GlobeNewsWire
- 24 days ago - Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - Business Wire
- 4 weeks ago - Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 4 weeks ago - Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors - GlobeNewsWire